Intitiation of satralizumab during pregnancy for successful childbirth in neuromyelitis optica spectrum disorder: A case report and literature review - PubMed
4 hours ago
- #Pregnancy
- #Neuromyelitis Optica Spectrum Disorder
- #Satralizumab
- Satralizumab initiated at 28+3 weeks gestation in a 32-year-old NMOSD patient to prevent pregnancy-associated relapse.
- Successful vaginal delivery at 40+1 weeks without peripartum complications or disease relapse.
- Transplacental transfer of satralizumab occurred, but drug was undetectable in breast milk; neonate developed normally.
- First reported case of satralizumab initiation during pregnancy for NMOSD relapse prevention.
- Suggests satralizumab may be a viable therapeutic option for NMOSD management in established pregnancy.